arrow
K

Kyoung Eun Lee

Ewha Womans University
H指数:19
被引数:1,749

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)

韩国全国范围内帕博西利(palbociclib)在HR(+)、HER2(−)转移性乳腺癌患者中的真实世界实践模式与临床数据(KCSG BR21-15)

2025-05-120
OA
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
2024-01-280
OAAI
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)

nivolumab联合eribulin在HER2-negative转移性乳腺癌中的临床活性: IB/II期研究 (KCSG BR18-16)

2023-12-012
OA
Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study
2023-03-010
PRE
Genomic characterization of hormone receptor-positive advanced breast cancer with high tumor mutational burden: fresh-frozen tissue genomic analysis from MUTATION-1 study (KCSG BR17-04)
2023-03-010
PRE
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group

基于电子病历的真实世界数据的数据收集框架,以评估癌症药物的有效性和安全性: 韩国癌症研究小组的一项全国性真实世界研究

2022-11-022
OAAI
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
BREAST
IF7.9
2022-10-012
OAAI
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17)
2022-02-150
PRE
Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04)
2022-02-151
PRE
A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15)
2022-02-150
PRE